Search company, investor...

Ironwood Pharmaceuticals

ironwoodpharma.com

Founded Year

1998

Stage

IPO | IPO

Total Raised

$307.3M

Date of IPO

2/12/2010

Market Cap

1.80B

Stock Price

11.78

About Ironwood Pharmaceuticals

Ironwood (formally known as Mircobia) creates and develops human medicines.

Headquarters Location

320 Bent Street

Cambridge, Massachusetts, 02141,

United States

617-621-7722

Missing: Ironwood Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ironwood Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ironwood Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ironwood Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ironwood Pharmaceuticals Patents

Ironwood Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Gastrointestinal tract disorders
  • Amines
  • Diseases of intestines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/6/2017

1/12/2021

Dosage forms, Pharmaceutical industry, Pharmacokinetics, Drug delivery devices, Amines

Grant

Application Date

7/6/2017

Grant Date

1/12/2021

Title

Related Topics

Dosage forms, Pharmaceutical industry, Pharmacokinetics, Drug delivery devices, Amines

Status

Grant

Latest Ironwood Pharmaceuticals News

Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022

11/22/2022 | 04:03pm EST Message : *Required fields Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 4:30 p.m. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com . To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts. We routinely post information that may be important to investors on our website at www.ironwoodpharma.com . In addition, follow us on Twitter and on LinkedIn . View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005006/en/ © Business Wire 2022

Ironwood Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ironwood Pharmaceuticals Rank

Ironwood Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Ironwood Pharmaceuticals founded?

    Ironwood Pharmaceuticals was founded in 1998.

  • Where is Ironwood Pharmaceuticals's headquarters?

    Ironwood Pharmaceuticals's headquarters is located at 320 Bent Street, Cambridge.

  • What is Ironwood Pharmaceuticals's latest funding round?

    Ironwood Pharmaceuticals's latest funding round is IPO.

  • How much did Ironwood Pharmaceuticals raise?

    Ironwood Pharmaceuticals raised a total of $307.3M.

  • Who are the investors of Ironwood Pharmaceuticals?

    Investors of Ironwood Pharmaceuticals include Astellas Venture Management, Venrock, Polaris Partners, F-Prime Capital, Fidelity Investments and 16 more.

  • Who are Ironwood Pharmaceuticals's competitors?

    Competitors of Ironwood Pharmaceuticals include GeoVax, Vitae Pharmaceuticals, Creative Biomolecules, Cara Therapeutics, AI2 and 12 more.

Compare Ironwood Pharmaceuticals to Competitors

N
Novalar Pharmaceuticals

Novalar Pharmaceuticals develops a drug agent that is designed to reverse the effects of local anesthesia applied in dental procedures, thereby allowing patients to return to their daily activities without the speech impediments, lip biting, and difficulty in eating that can be caused by unintended soft-tissue anesthesia.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

R
Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals offers CombinatoRx which is creating new combination medicines that attack disease on multiple fronts

N
Neuronyx

Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

P
Palkion

Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on the discovery and development of compounds that inhibit prolyl hydroxylase enzymes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.